Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating With Composite Clinical Score of Cognition and Function in Alzheimer’s Disease

A 2-Stage Model of Heterogenous Treatment Effects for Brain Atrophy in MS Utilizing the MS PATHS Research Network